Illumina Faces Battle to Save Grail Deal From EU Veto
- EU officials currently leaning toward opposing the takeover
- Illumina has chance to offer the EU commitments by Friday
Source: Grail Inc.
This article is for subscribers only.
Illumina Inc. faces a battle to save its $8 billion bid for cancer-test provider Grail from a European Union veto ahead of a Friday deadline to allay antitrust concerns.
EU officials are currently leaning toward blocking the deal by a March 4 deadline, according to people familiar with the review who asked not to be identified because a decision isn’t final. Illumina could still win over regulators by making acceptable concessions by Jan. 28.